← Back to Search

Other

Cohort 1 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 25
Awards & highlights

Study Summary

This trial examines how 2 drugs affect the body's absorption of a 3rd drug in healthy people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 25
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 25 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cohort 1: Area Under the Plasma Concentration-time Curve Up to Time t (AUC0-t) of DC-806
Cohort 1: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of DC-806
Cohort 1: Maximum Observed Plasma Concentrations (Cmax) of DC-806
+3 more
Secondary outcome measures
Cohorts 1 and 2: Number of Participants who Experience an Adverse Event

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment2 Interventions
Participants in Cohort 2 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with carbamazepine after the wash-out period.
Group II: Cohort 1Experimental Treatment2 Interventions
Participants in Cohort 1 will receive DC-806 single dose on Day 1, and the second dose of DC-806 along with itraconazole after the wash-out period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DC-806
2023
Completed Phase 1
~70
Itraconazole
2017
Completed Phase 2
~780
Carbamazepine
2016
Completed Phase 4
~2690

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyLead Sponsor
5 Previous Clinical Trials
345 Total Patients Enrolled
DICE Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
237 Total Patients Enrolled

Media Library

DC-806 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05994807 — Phase 1
Healthy Subjects Research Study Groups: Cohort 1, Cohort 2
Healthy Subjects Clinical Trial 2023: DC-806 Highlights & Side Effects. Trial Name: NCT05994807 — Phase 1
DC-806 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05994807 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible to participate in this medical investigation?

"Eligible candidates for this medical trial should be physically sound and between the ages of 18-55. Currently, 32 participants are being sought after."

Answered by AI

What regulatory status has Cohort 1 achieved?

"As the initial stage of a clinical trial, Cohort 1 has not been extensively tested for safety and efficacy. Consequently, our team at Power judged it to be a score of 1 on the scale from 1 to 3."

Answered by AI

Is eligibility for this trial restricted to people under the age of 35?

"According to the requirements, individuals eligible for this medical trial must be within an age range of 18 and 55 years old."

Answered by AI

Are there any unfilled vacancies for participants in this research project?

"Confirmed. The clinical trial's details, which were initially posted on August 8th 2023 and later updated on the 9th of that same month, are accessible to view via clinicaltrials.gov. This study is enrolling 32 patients from a single centre."

Answered by AI

How many volunteers are being accepted into this research project?

"Indeed, the information on clinicaltrials.gov reveals that recruitment is ongoing for this trial which was initially posted in August 8th 2023 and last updated a day later. A total of 32 people will be accepted at one medical centre."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
2023. "A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05994807.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top